Evidence map›Paper›PMID 42368558›Full record

ArticleActa pharmaceutica Sinica. B2026

Microthrombi targeted nano-micelle synchronizing endothelial gap opening and matrix decompression for augmenting drug perfusion within pancreatic cancer.

Mengnan Yang, Yuqing Tong, Shaoping Yin, Hengchuan Zhang, Xiaowen Huang, Kai Yuan, Yanfei Hao, Jianping Zhou, Meirong Huo, Tingjie Yin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mengnan YangDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing 211198, China.
Yuqing TongDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing 211198, China.
Shaoping YinExternal Medication Development and Application, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Hengchuan ZhangDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing 211198, China.
Xiaowen HuangDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing 211198, China.
Kai YuanDepartment of General Surgery, The First Affiliated Hospital of Shandong First Medical University, Jinan 250014, China.
Yanfei HaoCheeloo College of Medicine, Shandong University, Jinan 250012, China.
Jianping ZhouDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing 211198, China.
Meirong HuoDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing 211198, China.
Tingjie YinDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing 211198, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Local inhibition of the "patching" function of tumor-associated platelets against neutrophil infiltration-caused vascular breaches has been used as an "enhanced permeability and retention (EPR) amplification" strategy. Nevertheless, the vascular leakage-resulted elevation of interstitial fluid pressure (IFP) could impact tumoral perfusion and convection of nanodrugs. Especially for hypoperfused and desmoplastic pancreatic ductal adenocarcinoma (PDAC), solely relying on vascular destruction would predictably diminish tumoral drug perfusion. According to multi-thrombosis formation in PDAC, a microthrombi and matrix co-targeted dasatinib (DAS) nano-micelle (CPHD/DAS) synchronizing endothelial gap opening and matrix decompression was constructed for sustained augmentation of drug perfusion within PDAC. CPHD/DAS was composed of CREKA peptide-modified hyaluronic acid-deoxycholate conjugates co-assembled with DAS.

Indexed as

AntiplateletsBlood perfusionEndothelial barrierInterstitial fluid pressureMicelle-based nanodrugPancreatic ductal adenocarcinomaPancreatic stellate cellsTumor matrix

Identifiers

PMID42368558
PMCPMC13305164

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.